Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata

November 2023 in “ Pakistan Journal of Health Sciences ”

Danyal Sajjad, Bushra Muzaffar, Muhammad Adeel Siddiqui, Majid Hussain, Sana Aslam, Huma Farid

tacrolimus clobetasol propionate alopecia areata hair re-growth Protopic Clobex AA

Studysummary This study found that clobetasol propionate 0.05% was significantly more effective in stimulating hair re-growth in alopecia areata patients compared to topical tacrolimus 0.1%, with an excellent response observed in 74.3% of the clobetasol group versus 40% in the tacrolimus group. Our plain-language summary of this paper — not a Tressless recommendation.

In a study comparing the efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% for treating alopecia areata, 70 patients aged 20 to 50 were treated over 3 months. Group A used clobetasol propionate and Group B used tacrolimus. Results showed that 74.3% of patients in Group A experienced excellent hair re-growth, compared to 40% in Group B, with a significant p-value of 0.028. The study concluded that clobetasol propionate 0.05% is more effective for stimulating hair re-growth in alopecia areata patients.

View this study on thejas.com.pk →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

Efficacy of Topical Clobetasol Propionate 0.05% Ointment and Topical Tacrolimus 0.1% Ointment in Treatment of Alopecia Areata: Randomized Controlled Trial

research Efficacy of Topical Clobetasol Propionate 0.05% Ointment and Topical Tacrolimus 0.1% Ointment in Treatment of Alopecia Areata: Randomized Controlled Trial

June 2022 in “Pakistan Journal of Medical and Health Sciences”

This randomized controlled trial found that topical clobetasol propionate 0.05% ointment is significantly more effective than topical tacrolimus 0.1% ointment in promoting hair regrowth in patients with alopecia areata, with effective results observed in 79.31% of clobetasol users compared to 44.82% of tacrolimus users.

research Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with Alopecia Areata

14 citations , September 2021 in “Journal of Inflammation Research”

This study suggests that female patients with alopecia areata, especially those with nail abnormalities and atopic diseases, may have higher rates of coexisting autoimmune diseases.

Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata

Research cited in this study

research Efficacy of Topical Clobetasol Propionate 0.05% Ointment and Topical Tacrolimus 0.1% Ointment in Treatment of Alopecia Areata: Randomized Controlled Trial

research Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with Alopecia Areata

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

research A Review of the Most Common Dermatologic Conditions and Their Debilitating Psychosocial Impacts

research Alopecia Areata: A Multifactorial Autoimmune Condition

research Comorbidities in Alopecia Areata: A Systematic Review and Meta-Analysis

research Factors Associated With Severity Of Alopecia Areata

research Efficacy of Topical Sensitizers in the Treatment of Alopecia Areata